さまざまな形態の治験薬タファミジスが健康な成人においてどのように血中に取り込まれるかを知るための研究
絶食条件下で投与された市販の 61 mg タファミジス遊離酸カプセルに対する 61 mg および 70 mg タファミジス遊離酸錠剤の相対的な生物学的利用能を推定するための第 1 相、非盲検、ランダム化、3 治療、3 期間、クロスオーバー、単回用量試験健康な成人参加者の割合
The purpose of this clinical trial is to compare the amount of tafamidis in the blood of healthy adult participants after taking three different forms of tafamidis by mouth.
調査の概要
状態
条件
詳細な説明
A new tafamidis free acid tablet is being developed to be bioequivalent to the current commercial 61 mg tafamidis free acid capsule. The purpose of the study is to estimate the relative bioavailability of 61 mg tafamidis free acid tablet (Test 1) and 70 mg tafamidis free acid tablet (Test 2) to 61 mg tafamidis free acid capsule (Reference, the clinical supply form of the current commercial 61 mg tafamidis free acid capsule) administered under fasted conditions in healthy adult participants.
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Bruxelles-capitale, Région de
-
Brussels、Bruxelles-capitale, Région de、ベルギー、B-1070
- Pfizer Clinical Research Unit - Brussels
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Age and Sex:
-
Participants aged 18 years or older (or the minimum age of consent in accordance with local regulations) at screening.
-
Healthy female participants of nonchildbearing potential and/or male participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests.
Other Inclusion Criteria:
-
BMI of 16-32 kg/m2; and a total body weight >45 kg (99 lb).
Exclusion Criteria:
Medical Conditions:
-
Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
- History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, HBcAb, or HCVAb. Hepatitis B vaccination is allowed.
- Hypersensitivity to any component of the formulations.
-
Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
Prior/Concomitant Therapy:
-
Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of study intervention.
-
Current use of any prohibited concomitant medication(s) or participant unwilling or unable to use a required concomitant medication(s).
Prior/Concurrent Clinical Study Experience:
-
Previous administration of an investigational product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer).
Diagnostic Assessments:
-
A positive urine drug test. A single repeat for positive drug screen may be allowed.
-
Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic) for participants <60 years; and ≥150/90 mm/Hg for participants ≥60 years old, following at least 5 minutes of supine rest. If systolic BP is ≥140 or 150 mm Hg (based on age) or diastolic ≥90 mm Hg, the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
-
Standard 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, QTcF >450 ms, complete LBBB, signs of an acute or indeterminate age myocardial infarction, ST-T interval changes suggestive of myocardial ischemia, second or third degree AV block, or serious bradyarrhythmias or tachyarrhythmias). If QTcF exceeds 450 ms, or QRS exceeds 120 ms, the ECG should be repeated twice and the average of the 3 QTcF or QRS values used to determine the participant's eligibility. Computer-interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding a participant.
-
Renal impairment as defined by an eGFR of <60 mL/min/1.73 m².
-
Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:
• ALT, AST, Bilirubin ≥1.5 × ULN. Participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ULN.
Other Exclusion Criteria:
-
History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit, or 3 ounces (90 mL) of wine).
-
Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.
-
Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Test 1 tablet followed by Test 2 tablet followed by Reference capsule
On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug |
Tafamidis 61 mg free acid tablet (Test 1) Tafamidis 61 mg free acid tablet (Test 1) Tafamidis 61 mg free acid capsule (Reference) |
|
実験的:Test 1 tablet followed by Reference capsule followed by Test 2 tablet
On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug |
Tafamidis 61 mg free acid tablet (Test 1) Tafamidis 61 mg free acid tablet (Test 1) Tafamidis 61 mg free acid capsule (Reference) |
|
実験的:Test 2 tablet followed by Reference capsule followed by Test 1 tablet
On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug |
Tafamidis 61 mg free acid tablet (Test 1) Tafamidis 61 mg free acid tablet (Test 1) Tafamidis 61 mg free acid capsule (Reference) |
|
実験的:Test 2 tablet followed by Test 1 tablet followed by Reference capsule
On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug |
Tafamidis 61 mg free acid tablet (Test 1) Tafamidis 61 mg free acid tablet (Test 1) Tafamidis 61 mg free acid capsule (Reference) |
|
実験的:Reference capsule followed by Test 1 tablet followed by Test 2 tablet
On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug |
Tafamidis 61 mg free acid tablet (Test 1) Tafamidis 61 mg free acid tablet (Test 1) Tafamidis 61 mg free acid capsule (Reference) |
|
実験的:Reference capsule followed by Test 2 tablet followed by Test 1 tablet
On Day 1 of each period, participants will receive a single dose of 1 of the tafamidis formulations. Each period is separated by a washout of at least 16 days between administration of study drug |
Tafamidis 61 mg free acid tablet (Test 1) Tafamidis 61 mg free acid tablet (Test 1) Tafamidis 61 mg free acid capsule (Reference) |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Area under the concentration-time curve (AUCinf)
時間枠:Hour 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168
|
Area under the plasma concentration time profile from time zero extrapolated to infinite time |
Hour 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168
|
|
Maximum observed plasma concentration (Cmax)
時間枠:Hour 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168
|
Peak or maximum observed concentration |
Hour 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Pfizer CT.gov Call Center、Pfizer
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- B3461114
- 2023-509241-12-00 (レジストリ識別子:CTIS (EU))
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。